Pancreatic Cancer Has Genetic Early Warning System
Researchers have discovered how cellular stress and inflammation drive pancreatic cancer progression via the STAT3-ITGB3 pathway.
Researchers have discovered how cellular stress and inflammation drive pancreatic cancer progression via the STAT3-ITGB3 pathway.
A new prospective study in BMC Cancer shows that the blood-based multi-omics test SeekInClarity accurately predicts treatment outcomes.
ClearNote Health and University Hospital Southampton have launched the SAFE-D study to evaluate the Avantect Pancreatic Cancer Test.
A new research study identifies lncRNAs CBR3-AS1 and PCA3 as significantly overexpressed in gastric cancer tissues.
Read MoreForesight Diagnostics and QIAGEN have entered a global partnership to develop and commercialize a companion diagnostic kit for lymphoma.
Read MoreGuardant Health’s Shield MCD test has received FDA Breakthrough Device designation for its ability to detect multiple cancer types.
Read MorePersonalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Read MoreNew Day Diagnostics has launched ColoHealth, a physician-mediated blood test for colorectal cancer screening.
Read MoreLabcorp has expanded its precision oncology portfolio with new tests for solid tumors and blood cancers to support diagnostic development.
Read MoreSAGA Diagnostics has launched Pathlight, a groundbreaking multi-cancer blood test for ultra-sensitive detection of MRD.
Read MoreHologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
Read MoreForesight Diagnostics announced the independent validation of its CLARITY MRD assay, showing strong prognostic performance.
Read MoreA strategic partnership has formed to accelerate the development a test for early ovarian cancer diagnosis using AI-powered analytics.
Read MoreResearchers developed an AI-driven blood test, ARTEMIS-DELFI, that detects pancreatic cancer treatment response faster and more accurately.
Read MoreThe FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read MoreA groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
Read MoreOncologists are seeing more advanced cancer cases due to screening barriers and are concerned current tests aren’t effective enough.
Read MoreTeal Health has received FDA approval for the Teal Wand, a prescription-based self-collection device for cervical cancer screening.
Read More